Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 120
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Naunyn Schmiedebergs Arch Pharmacol ; 390(2): 163-173, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27889808

RESUMEN

The purpose of this study was to determine feasibility of a novel therapeutic approach to drug-induced voiding after spinal cord injury (SCI) using a well-characterized, peptide, neurokinin 2 receptor (NK2 receptor) agonist, Lys5, MeLeu9, Nle10-NKA(4-10) (LMN-NKA). Cystometry and colorectal pressure measurements were performed in urethane-anesthetized, intact, and acutely spinalized female rats. Bladder pressure and voiding were monitored in response to intravenous LMN-NKA given with the bladder filled to 70% capacity. LMN-NKA (0.1-300 µg/kg) produced dose-dependent, rapid (<60 s), short-duration (<15 min) increases in bladder pressure. In intact rats, doses above 0.3-1 µg/kg induced urine release (voiding efficiency of ~70% at ≥1 µg/kg). In spinalized rats, urine release required higher doses (≥10 µg/kg) and was less efficient (30-50%). LMN-NKA (0.1-100 µg/kg) also produced dose-dependent increases in colorectal pressure. No tachyphylaxis was observed, and the responses were blocked by an NK2 receptor antagonist (GR159897, 1 mg/kg i.v.). No obvious cardiorespiratory effects were noted. These results suggest that rapid-onset, short-duration, drug-induced voiding is possible in acute spinal and intact rats with intravenous administration of an NK2 receptor agonist. Future challenges remain in regard to finding alternative routes of administration that produce clinically significant voiding, multiple times per day, in animal models of chronic SCI.


Asunto(s)
Colon/efectos de los fármacos , Motilidad Gastrointestinal/efectos de los fármacos , Contracción Muscular/efectos de los fármacos , Neuroquinina A/análogos & derivados , Fragmentos de Péptidos/farmacología , Traumatismos de la Médula Espinal/tratamiento farmacológico , Vejiga Urinaria/efectos de los fármacos , Urodinámica/efectos de los fármacos , Animales , Colon/inervación , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Estudios de Factibilidad , Femenino , Indoles/farmacología , Neuroquinina A/farmacología , Piperidinas/farmacología , Presión , Ratas Sprague-Dawley , Receptores de Neuroquinina-2/efectos de los fármacos , Receptores de Neuroquinina-2/metabolismo , Traumatismos de la Médula Espinal/metabolismo , Traumatismos de la Médula Espinal/fisiopatología , Factores de Tiempo , Vejiga Urinaria/inervación
2.
J Pharmacol Exp Ther ; 356(1): 13-9, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26607257

RESUMEN

Bites by tarantulas (Theraphosidae, Mygalomorphae) in humans can result in mild clinical manifestations such as local pain, erythema, and edema. Vitalius dubius is a medium-sized, nonaggressive theraphosid found in southeastern Brazil. In this work, we investigated the mediators involved in the plasma extravasation caused by V. dubius venom in rats. The venom caused dose-dependent (0.1-100 µg/site) edema in rat dorsal skin. This edema was significantly inhibited by ((S)1-{2-[3(3-4-dichlorophenyl)-1-(3-iso-propoxyphenylacetyl)piperidine-3-yl]ethyl}-4-phenyl-1-azoniabicyclo[2.2.2]octone, chloride) (SR140333, a neurokinin NK1 receptor antagonist), indomethacin [a nonselective cyclooxygenase (COX) inhibitor], cyproheptadine (a serotonin 5-hydroxytryptamine1/2 and histamine H1 receptor antagonist), and N(ω)-nitro-L-arginine methyl ester (a nitric oxide synthase inhibitor). In contrast, mepyramine (a histamine H1 receptor antagonist), D-Arg-[Hyp(3),Thi(5),D-Tic(7),Oic(8)-]-BK (JE 049, a bradykinin B2 receptor antagonist), and ((S)-N-methyl-N-[4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-di-chlorophenyl)butyl]benzamide) (SR48968, a neurokinin NK2 receptor antagonist) had no effect on the venom-induced increase in vascular permeability. In rat hind paws, the venom-induced edema was attenuated by ketoprofen (a nonselective COX inhibitor) administered 15 minutes postvenom. Preincubation of venom with commercial antiarachnid antivenom attenuated the venom-induced edema. These results suggest that the enhanced vascular permeability evoked by V. dubius venom involves serotonin, COX products, neurokinin NK1 receptors, and nitric oxide formation. The attenuation of hind paw edema by ketoprofen suggests that COX inhibitors could be useful in treating the local inflammatory response to bites by these spiders.


Asunto(s)
Edema/inducido químicamente , Edema/patología , Piperidinas/uso terapéutico , Quinuclidinas/uso terapéutico , Venenos de Araña/toxicidad , Animales , Antiinflamatorios no Esteroideos/uso terapéutico , Inhibidores de la Ciclooxigenasa/uso terapéutico , Ciproheptadina/uso terapéutico , Relación Dosis-Respuesta a Droga , Edema/tratamiento farmacológico , Pie/patología , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Indometacina/uso terapéutico , Cetoprofeno/uso terapéutico , Masculino , NG-Nitroarginina Metil Éster/uso terapéutico , Antagonistas del Receptor de Neuroquinina-1/uso terapéutico , Óxido Nítrico Sintasa/antagonistas & inhibidores , Ratas , Ratas Wistar , Receptores de Neuroquinina-2/efectos de los fármacos , Antagonistas de la Serotonina/uso terapéutico , Piel/patología
3.
Neuropeptides ; 47(1): 9-18, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22938860

RESUMEN

The present study was planned to evaluate role of tachykinins (TKs) and neurokinin (NK) receptors in the regulation of gastric motility in sheep. We examined the effects of intravenous (i.v.) injection of neurokinin A (NKA) and substance P (SP) on motility of the rumen, omasum, and abomasum in conscious sheep and the effects of NK receptor blockade on the effect of TKs using NK-1 receptor antagonist L-732,138 and NK-2 receptor antagonist SR48968. Moreover, the effect of NK receptor blockade on omasal cyclic contractions was examined. Intravenous injection of NKA and SP induced tonic contraction of rumen, omasum, and abomasum, and the contractile effect of NKA was more potent than that of SP in all the gastric regions. Although the effect of SP was not inhibited by L-732,138, the effect of NKA was significantly inhibited by SR48968. However, single infusion of SR48968 and L-732,138 did not alter cyclic electromyographic activity and basal intraluminal pressure in the omasum. These results imply that NKA and NK-2 receptors play a primary role in non-cholinergic regulation of ovine gastric motility, though NK-2 and NK-1 receptors seem unlikely to be involved in the physiological regulation of omasal cyclic contractions.


Asunto(s)
Abomaso/efectos de los fármacos , Motilidad Gastrointestinal/efectos de los fármacos , Receptores de Neuroquinina-2/fisiología , Rumen/efectos de los fármacos , Taquicininas/fisiología , Animales , Benzamidas/farmacología , Inyecciones Intravenosas , Cinética , Masculino , Contracción Muscular/fisiología , Neuroquinina A/administración & dosificación , Neuroquinina A/farmacología , Omaso/efectos de los fármacos , Piperidinas/farmacología , Receptores de Neuroquinina-2/antagonistas & inhibidores , Receptores de Neuroquinina-2/efectos de los fármacos , Ovinos , Sustancia P/farmacología , Triptófano/análogos & derivados , Triptófano/farmacología
4.
J Pharmacol Exp Ther ; 340(1): 27-36, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21957267

RESUMEN

Hemokinin-1 (HK-1) is a newly identified tachykinin, originating from the immune system rather than neurons, and may participate in the immune and inflammatory response. In colonic mucosa of patients with inflammatory bowel disease (IBD), up-regulation of the TAC4 gene encoding HK-1 and increased production of prostaglandin E2 (PGE2) occur. Our aim was to examine the mechanistic link between human HK-1 and PGE2 production in normal human colon. Exogenous HK-1 (0.1 µM) for 4 h evoked an increased PGE2 release from colonic mucosal and muscle explants by 10- and 3.5-fold, respectively, compared with unstimulated time controls. The HK-1-stimulated PGE2 release was inhibited by the tachykinin receptor antagonists (S)1-2-[3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenylacetyl)piperidin-3-yl]ethyl-4-phenyl-l azonia-bicyclo[2.2.2]octane (SR140333) [neurokinin-1 (NK1)] and N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide (SR48968) [neurokinin-2 (NK2)] and was also inhibited by the cyclooxygenase (COX)-2 inhibitor N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide) (NS-398) but not by the COX-1 inhibitor 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole (SC-560). A parallel study with substance P showed similar results. Molecular studies with HK-1-treated explants demonstrated a stimulatory effect on COX-2 expression at both transcription and protein levels. It is noteworthy that this was coupled with HK-1-induced down-regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) mRNA and protein expression. Immunoreactivity for 15-PGDH occurred on inflammatory cells, epithelial cells, platelets, and ganglia. This finding provides an additional mechanism for HK-1-evoked PGE2 increase, in which HK-1 may interfere with the downstream metabolism of PGE2 by suppressing 15-PGDH expression. In conclusion, our results uncover a novel inflammatory role for HK-1, which signals via NK1 and NK2 receptors to regulate PGE2 release from human colonic tissue, and may further explain a pathological role for HK-1 in IBD when abnormal levels of PGE2 occur.


Asunto(s)
Colon/metabolismo , Ciclooxigenasa 2/metabolismo , Dinoprostona/biosíntesis , Inhibidores Enzimáticos/farmacología , Hidroxiprostaglandina Deshidrogenasas/antagonistas & inhibidores , Taquicininas/farmacología , Adulto , Anciano , Western Blotting , Colitis/fisiopatología , Colon/efectos de los fármacos , Colon/enzimología , Relación Dosis-Respuesta a Droga , Activación Enzimática/efectos de los fármacos , Ensayo de Inmunoadsorción Enzimática , Femenino , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Humanos , Inmunohistoquímica , Técnicas In Vitro , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Masculino , Persona de Mediana Edad , Músculo Liso/efectos de los fármacos , Músculo Liso/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Receptores de Neuroquinina-1/efectos de los fármacos , Receptores de Neuroquinina-1/fisiología , Receptores de Neuroquinina-2/efectos de los fármacos , Receptores de Neuroquinina-2/fisiología , Estimulación Química , Taquicininas/antagonistas & inhibidores
5.
J Physiol ; 588(Pt 9): 1541-9, 2010 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-20231139

RESUMEN

Substance P (SP) and its receptors are involved in anxiety-related behaviours and regulate the intake of drugs of abuse and alcohol. Within the midbrain ventral tegmental area (VTA), a region that is clearly involved in the control of these behaviours, SP is released by stress and has been shown to trigger relapse. SP activates neurokinin (NK) receptors, which excites midbrain dopamine (DA) neurons and leads to increased DA in target regions. In this study, we have investigated the mechanisms underlying SP actions in the VTA, specifically investigating interactions between SP and GABA(B) receptors. We show that in VTA neurons, NK receptor activation closes an inwardly rectifying potassium channel, and moreover inhibits GABA(B) receptor-mediated transmission through an interaction that depends upon phospholipase C (PLC), intracellular calcium and protein kinase C (PKC).


Asunto(s)
Antagonistas del GABA , Antagonistas de Receptores de GABA-B , Receptores de Neuroquinina-2/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Sustancia P/farmacología , Área Tegmental Ventral/efectos de los fármacos , Animales , Baclofeno/farmacología , Quelantes/farmacología , Dopamina/fisiología , Ácido Egtácico/análogos & derivados , Ácido Egtácico/farmacología , Electrofisiología , Canales de Potasio Rectificados Internamente Asociados a la Proteína G/efectos de los fármacos , Agonistas del GABA/farmacología , Inmunohistoquímica , Técnicas In Vitro , Masculino , Potenciales de la Membrana/efectos de los fármacos , Técnicas de Placa-Clamp , Proteína Quinasa C/fisiología , Ratas , Ratas Sprague-Dawley , Receptores de Neuroquinina-1/efectos de los fármacos , Tirosina 3-Monooxigenasa/metabolismo
6.
J Anesth ; 23(4): 620-3, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19921381

RESUMEN

We previously reported that desflurane induced airway contraction via antidromic tachykinin release from sensory C-fibers. Here, we investigated the effect of desflurane on airway lung resistance (R(L)) using specific receptor antagonists in C-fibers. Young guinea pigs were anesthetized and their tracheas were cannulated with an endotracheal tube via a tracheotomy. A Fleisch pneumotachograph and a differential transducer were used to monitor respiratory flow rate, intrapleural pressure, and airway pressure, and R(L) was calculated and recorded. A transient receptor potential A1 (TRPA1) or a transient receptor potential V1 (TRPV1) selective antagonist of sensory C-fibers, i.e., HC030031 or BCTC, was administered before the exposure to desflurane. In an additional experiment, tachykinin receptor of airway smooth muscles was antagonized only by the neurokinin-2 receptor antagonist MEN-10376 before the exposure to desflurane. HC030031 completely inhibited both the first and the second contractile responses induced by desflurane, whereas BCTC had little effect. MEN-10376 also significantly and substantially diminished the contractile response. Desflurane contracts the airway in untreated guinea pigs mainly by activating irritant gas receptor TRPA1 of afferent C-fibers, resulting in the release of contractile tachykinins such as neurokinin A.


Asunto(s)
Resistencia de las Vías Respiratorias/efectos de los fármacos , Anestésicos por Inhalación/farmacología , Isoflurano/análogos & derivados , Fibras Nerviosas Amielínicas/efectos de los fármacos , Células Receptoras Sensoriales/efectos de los fármacos , Canales Catiónicos TRPC/efectos de los fármacos , Animales , Desflurano , Cobayas , Isoflurano/farmacología , Masculino , Receptores de Neuroquinina-2/efectos de los fármacos , Taquicininas/metabolismo
7.
J Med Chem ; 52(19): 5999-6011, 2009 Oct 08.
Artículo en Inglés | MEDLINE | ID: mdl-19746979

RESUMEN

The neurokinin NK2 receptor is known to pre-exist in equilibrium between at least three states: resting-inactive, calcium-triggering, and cAMP-producing. Its endogeneous ligand, NKA, mainly induces the calcium response. Using a FRET-based assay, we have previously discovered an allosteric modulator of the NK2 receptor that has the unique ability to discriminate among the two signaling pathways: calcium-signaling is not affected while cAMP signaling is significantly decreased. A series of compounds have been prepared and studied in order to better understand the structural determinants of this allosteric functional switch of a GPCR. Most of them display the same allosteric profile, with smooth pharmacomodulation. One compound however exhibits significantly improved modulatory properties of NKA induced signaling when compared to the original modulator.


Asunto(s)
Regulación Alostérica , Neuroquinina A/química , Receptores de Neuroquinina-2/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Animales , Señalización del Calcio , AMP Cíclico , Transferencia Resonante de Energía de Fluorescencia , Humanos , Hidrocarburos Aromáticos/química , Hidrocarburos Aromáticos/farmacología , Ligandos , Neuroquinina A/metabolismo , Conformación Proteica/efectos de los fármacos , Receptores Acoplados a Proteínas G , Receptores de Neuroquinina-2/química , Receptores de Neuroquinina-2/metabolismo
8.
Am J Physiol Gastrointest Liver Physiol ; 297(2): G348-60, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19497956

RESUMEN

We investigated immunohistochemical differences in the distribution of TRPV1 channels and the contractile effects of capsaicin on smooth muscle in the mouse rectum and distal, transverse, and proximal colon. In the immunohistochemical study, TRPV1 immunoreactivity was found in the mucosa, submucosal, and muscle layers and myenteric plexus. Large numbers of TRPV1-immunoreactive axons were observed in the rectum and distal colon. In contrast, TRPV1-positive axons were sparsely distributed in the transverse and proximal colon. The density of TRPV1-immunoreactive axons in the rectum and distal colon was much higher than those in the transverse and proximal colon. Axons double labeled with TRPV1 and protein gene product (PGP) 9.5 were detected in the myenteric plexus, but PGP 9.5-immunoreactive cell bodies did not colocalize with TRPV1. In motor function studies, capsaicin induced a fast transient contraction, followed by a large long-lasting contraction in the rectum and distal colon, whereas in the transverse and proximal colon only the transient contraction was observed. The capsaicin-induced transient contraction from the proximal colon to the rectum was moderately inhibited by an NK1 or NK2 receptor antagonist. The capsaicin-induced long-lasting contraction in the rectum and distal colon was markedly inhibited by an NK2 antagonist, but not by an NK1 antagonist. The present results suggest that TRPV1 channels located on the rectum and distal colon play a major role in the motor function in the large intestine.


Asunto(s)
Capsaicina/farmacología , Colon/efectos de los fármacos , Motilidad Gastrointestinal/efectos de los fármacos , Contracción Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Plexo Mientérico/efectos de los fármacos , Recto/efectos de los fármacos , Canales Catiónicos TRPV/efectos de los fármacos , Animales , Atropina/farmacología , Colon/inervación , Colon/metabolismo , Relación Dosis-Respuesta a Droga , Inmunohistoquímica , Técnicas In Vitro , Masculino , Ratones , Músculo Liso/inervación , Músculo Liso/metabolismo , Plexo Mientérico/metabolismo , Neuroquinina A/metabolismo , Pirazinas/farmacología , Piridinas/farmacología , Receptores de Neuroquinina-1/efectos de los fármacos , Receptores de Neuroquinina-1/metabolismo , Receptores de Neuroquinina-2/efectos de los fármacos , Receptores de Neuroquinina-2/metabolismo , Recto/inervación , Recto/metabolismo , Sustancia P/metabolismo , Canales Catiónicos TRPV/metabolismo , Tetrodotoxina/farmacología , Factores de Tiempo , Ubiquitina Tiolesterasa/análisis
9.
J Pharmacol Sci ; 110(1): 122-6, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19423952

RESUMEN

The effects of the monoamine oxidase A (MAO-A) inhibitor clorgyline, the L-type calcium-channel blocker nicardipine, the syntaxin inhibitor botulinum toxin type C, and the potent thiol-oxidant phenylarsine oxide (PAO) on the selective tachykinin NK(2)-receptor agonist [beta-Ala(8)]-neurokinin A(4-10) [betaAla-NKA-(4-10)]-evoked 5-hydroxytryptamine (5-HT) outflow from colonic enterochromaffin (EC) cells was investigated in vitro using isolated guinea-pig proximal colon. The betaAla-NKA-(4-10)-evoked outflow of 5-HT from clorgyline-treated colonic strips was markedly higher than that from clorgyline-untreated colonic strips. The betaAla-NKA-(4-10)-evoked 5-HT outflow from the clorgyline-treated colonic strips was sensitive to nicardipine or botulinum toxin type C. Moreover, PAO concentration-dependently suppressed the betaAla-NKA-(4-10)-evoked 5-HT outflow from the clorgyline-treated colonic strips. The suppressant action of PAO was reversed by the reducing agent dithiothrietol, but was not blocked by the protein tyrosine kinase inhibitor genistein. These results suggest that the tachykinin NK(2) receptor-triggered 5-HT release from guinea-pig colonic EC cells is mediated by syntaxin-related exocytosis mechanisms and that colonic mucosa MAO-A activity has the important function of modulating the tachykinin NK(2) receptor-triggered 5-HT release. It also appears that PAO-mediated sulfhydryl oxidation plays a role in modulating the tachykinin NK(2) receptor-triggered 5-HT release through a mechanism independent of inhibition of protein tyrosine phosphatase activity.


Asunto(s)
Colon/metabolismo , Receptores de Neuroquinina-2/fisiología , Serotonina/metabolismo , Animales , Arsenicales/farmacología , Toxinas Botulínicas/farmacología , Bloqueadores de los Canales de Calcio/farmacología , Clorgilina/farmacología , Colon/citología , Colon/efectos de los fármacos , Exocitosis/efectos de los fármacos , Cobayas , Ácido Hidroxiindolacético/metabolismo , Técnicas In Vitro , Masculino , Monoaminooxidasa/metabolismo , Inhibidores de la Monoaminooxidasa/farmacología , Nicardipino/farmacología , Oxidantes/farmacología , Oxidación-Reducción , Proteínas Tirosina Fosfatasas/antagonistas & inhibidores , Proteínas Qa-SNARE/fisiología , Receptores de Neuroquinina-2/efectos de los fármacos
10.
Eur J Pharmacol ; 601(1-3): 148-53, 2008 Dec 28.
Artículo en Inglés | MEDLINE | ID: mdl-18977217

RESUMEN

The preprotachykinin gene Tac4 expressed in murine uterus and placenta is thought to encode a peptide RSRTRQFYGLM-NH(2), mouse hemokinin 1. We have examined the uterotonic effects of mouse hemokinin 1 and its N-terminally truncated analogue, mouse hemokinin 1(2-11) on mouse uterus. Mouse hemokinin 1(2-11) was equieffective with but slightly less potent than substance P in tissues from non-pregnant Swiss mice. On myometrium from Balb C mice primed with oestrogen the positions of concentration-response curves to substance P and the mouse hemokinins were similar to those of neurokinin A, but the maximum responses were lower. The tachykinin NK(1) receptor antagonist, 1-{2-(3, 4-dichlorophenyl)-1-(3-isopropoxyphenylacetyl) piperidin-3-yl]ethyl}-4phenyl-1-azonia-bicyclo[2.2.2]octane (SR 140333), reduced the effects of the agonists in tissues from both groups of mice. In myometria from late pregnant (Days 17-18) Balb C mice the responses to mouse hemokinin 1(2-11) were less potent than in those from oestrogen-primed mice. Human hemokinin 1, the human orthologue of mouse hemokinin 1, was more effective than mouse hemokinin 1(2-11), while endokinin D was inactive. Mouse hemokinin 1 effects were blocked by SR 140333 alone and in combination with ((S)-N-methyl-N[4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl]benzamide (SR 48968) but not by SR 48968 alone. Thus the mouse hemokinins are tachykinin NK(1) receptor-preferring uterotonic agonists in non-pregnant mice but lack action at the myometrial tachykinin NK(2) receptors present in late pregnant mice.


Asunto(s)
Precursores de Proteínas/metabolismo , Receptores de Neuroquinina-1/metabolismo , Receptores de Neuroquinina-2/metabolismo , Taquicininas/metabolismo , Útero/metabolismo , Animales , Femenino , Ratones , Ratones Endogámicos BALB C , Miometrio/metabolismo , Neuroquinina A/farmacología , Embarazo , Preñez , Precursores de Proteínas/farmacología , Receptores de Neuroquinina-1/efectos de los fármacos , Receptores de Neuroquinina-2/efectos de los fármacos , Sustancia P/farmacología , Taquicininas/farmacología
11.
Br J Pharmacol ; 155(7): 1043-55, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18846038

RESUMEN

BACKGROUND AND PURPOSE: To characterize the in vitro motor patterns and the neurotransmitters released by enteric motor neurons (EMNs) in the human sigmoid colon. EXPERIMENTAL APPROACH: Sigmoid circular strips were studied in organ baths. EMNs were stimulated by electrical field stimulation (EFS) and through nicotinic ACh receptors. KEY RESULTS: Strips developed weak spontaneous rhythmic contractions (3.67+/-0.49 g, 2.54+/-0.15 min) unaffected by the neurotoxin tetrodotoxin (TTX; 1 microM). EFS induced strong contractions during (on, 56%) or after electrical stimulus (off, 44%), both abolished by TTX. Nicotine (1-100 microM) inhibited spontaneous contractions. Latency of off-contractions and nicotine responses were reduced by N(G)-nitro-L-arginine (1 mM) and blocked after further addition of apamin (1 microM) or the P2Y(1) receptor antagonist MRS 2179 (10 microM) and were unaffected by the P2X antagonist NF279 (10 microM) or alpha-chymotrypsin (10 U mL(-1)). Amplitude of on- and off-contractions was reduced by atropine (1 microM) and the selective NK(2) receptor antagonist Bz-Ala-Ala-D-Trp-Phe-D-Pro-Pro-Nle-NH(2) (1 microM). MRS 2179 reduced the amplitude of EFS on- and off-contractions without altering direct muscular contractions induced by ACh (1 nM-1 mM) or substance P (1 nM-10 microM). CONCLUSIONS AND IMPLICATIONS: Latency of EFS-induced off-contractions and inhibition of spontaneous motility by nicotine are caused by stimulation of inhibitory EMNs coreleasing NO and a purine acting at muscular P2Y(1) receptors through apamin-sensitive K(+) channels. EFS-induced on- and off-contractions are caused by stimulation of excitatory EMNs coreleasing ACh and tachykinins acting on muscular muscarinic and NK(2) receptors. Prejunctional P2Y(1) receptors might modulate the activity of excitatory EMNs. P2Y(1) and NK(2) receptors might be therapeutic targets for colonic motor disorders.


Asunto(s)
Colon Sigmoide/metabolismo , Receptores Muscarínicos/metabolismo , Receptores de Neuroquinina-2/metabolismo , Receptores Purinérgicos P2/metabolismo , Acetilcolina/administración & dosificación , Acetilcolina/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Colon Sigmoide/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Estimulación Eléctrica , Femenino , Humanos , Técnicas In Vitro , Masculino , Persona de Mediana Edad , Neuronas Motoras/efectos de los fármacos , Neuronas Motoras/metabolismo , Contracción Muscular/efectos de los fármacos , Contracción Muscular/fisiología , Nicotina/administración & dosificación , Nicotina/metabolismo , Óxido Nítrico/metabolismo , Receptores Muscarínicos/efectos de los fármacos , Receptores de Neuroquinina-2/efectos de los fármacos , Receptores Nicotínicos/efectos de los fármacos , Receptores Nicotínicos/metabolismo , Receptores Purinérgicos P2/efectos de los fármacos , Receptores Purinérgicos P2Y1 , Transmisión Sináptica/efectos de los fármacos , Transmisión Sináptica/fisiología , Taquicininas/metabolismo
12.
Br J Pharmacol ; 153(7): 1465-73, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18264120

RESUMEN

BACKGROUND AND PURPOSE: The bladder urothelium is now known to have active properties. Our aim was to investigate the contractile properties of the urinary mucosa in response to the tachykinin neurokinin A (NKA) and carbachol. EXPERIMENTAL APPROACH: Discrete concentration-response curves for carbachol and NKA were obtained in matched strips of porcine detrusor, mucosa and intact bladder, suspended in organ baths. The effects of inhibitors and tachykinin receptor antagonists were studied on NKA-mediated contractions in mucosal strips. Intact sections of bladder and experimental strips were processed for histology and immunohistochemistry. KEY RESULTS: All types of strips contracted to both carbachol and NKA. Mucosal responses to NKA (pD2 7.2) were higher than those in intact strips and were inhibited by the NK2 receptor antagonist SR48968 (pKB 9.85) but not the NK1 receptor antagonist SR140333, tetrodotoxin or indomethacin. Immunostaining for smooth muscle actin and vimentin occurred under the urothelium and on blood vessels. Desmin immunostaining and histological studies showed only sparse smooth muscle to be present in the mucosal strips. Removal of smooth muscle remnants from mucosal strips did not alter the responses to NKA. CONCLUSIONS AND IMPLICATIONS: This study has shown both functional and histological evidence for contractile properties of the mucosa, distinct from the detrusor. Mucosal contractions to NKA appear to be directly mediated via NK2 receptors. The main cell type mediating mucosal contractions is suggested to be suburothelial myofibroblasts. Mucosal contractions may be important in vivo for matching the luminal surface area to bladder volume.


Asunto(s)
Neuroquinina A/farmacología , Neurotransmisores/farmacología , Receptores de Neuroquinina-2/efectos de los fármacos , Vejiga Urinaria/efectos de los fármacos , Animales , Carbacol/administración & dosificación , Carbacol/farmacología , Relación Dosis-Respuesta a Droga , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Inmunohistoquímica , Membrana Mucosa/efectos de los fármacos , Membrana Mucosa/metabolismo , Contracción Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Músculo Liso/metabolismo , Neuroquinina A/administración & dosificación , Neurotransmisores/administración & dosificación , Receptores de Neuroquinina-2/metabolismo , Porcinos , Vejiga Urinaria/metabolismo , Urotelio/efectos de los fármacos , Urotelio/metabolismo
13.
Br J Pharmacol ; 150(8): 1022-30, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17351665

RESUMEN

BACKGROUND AND PURPOSE: An up-regulation of the sensory neural pathways in the lung has been implicated in asthma and chronic obstructive pulmonary disease (COPD) and is thought to contribute to mucus hypersecretion, an essential feature of both diseases. The aim of this study was to assess non-invasively the acute effects (up to 60 min) of sensory nerve stimulation by capsaicin in the lung, using magnetic resonance imaging (MRI). EXPERIMENTAL APPROACH: Male Brown Norway rats were imaged prior to and 10, 30 and 60 min after intra-tracheal challenge with capsaicin (30 microg kg(-1)) or vehicle (0.5% ethanol solution). In subsequent studies, pre-treatment with the transient receptor potential vanilloid (TRPV)-1 antagonist, capsazepine; the dual neurokinin (NK) 1 and NK2 receptor antagonist, DNK333 and the mast cell stabilizer, di-sodium cromoglycate (DSCG) was used to modulate the effects of capsaicin. KEY RESULTS: Diffuse fluid signals were detected by MRI in the lung as early as 10 min after capsaicin, remaining constant 30 and 60 min after treatment. Broncho-alveolar lavage (BAL) fluid analysis performed 60 min after capsaicin revealed increased mucin concentration. Capsazepine (3.5 mg kg(-1)), DNK333 (10 mg kg(-1)) but not DSCG (10 mg kg(-1)) administered prophylactically were able to block the effect of capsaicin in the airways. CONCLUSIONS AND IMPLICATIONS: These observations suggest that the fluid signals detected by MRI after capsaicin administration reflected predominantly the release of mucus following activation of sensory nerves. They point to the opportunity of non-invasively assessing with MRI the influence of neuronal mechanisms in animal models of asthma and COPD.


Asunto(s)
Capsaicina/farmacología , Células Caliciformes/efectos de los fármacos , Pulmón/efectos de los fármacos , Imagen por Resonancia Magnética , Moco/metabolismo , Neuronas Aferentes/efectos de los fármacos , Animales , Compuestos Aza/farmacología , Benzamidas/farmacología , Líquido del Lavado Bronquioalveolar/química , Líquido del Lavado Bronquioalveolar/citología , Capsaicina/análogos & derivados , Cromolin Sódico/farmacología , Células Caliciformes/metabolismo , Células Caliciformes/patología , Pulmón/inervación , Pulmón/metabolismo , Pulmón/patología , Masculino , Ratas , Ratas Endogámicas BN , Receptores de Neuroquinina-1/efectos de los fármacos , Receptores de Neuroquinina-1/metabolismo , Receptores de Neuroquinina-2/efectos de los fármacos , Receptores de Neuroquinina-2/metabolismo , Canales Catiónicos TRPV/efectos de los fármacos , Canales Catiónicos TRPV/metabolismo , Factores de Tiempo
14.
J Neurophysiol ; 97(4): 2605-11, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17267757

RESUMEN

The parasympathetic secretomotor innervation of the salivary glands originates from a longitudinal column of neurons in the medulla called the salivatory nucleus. The neurons innervating the parotid and von Ebner salivary glands are situated in the caudal extremity of the column designated as the inferior salivatory nucleus (ISN). Immunocytochemical investigations have demonstrated the presence of a number of neuropeptides surrounding the ISN neurons. We have examined the neurophysiological effect of two of these neuropeptides on neurons of the ISN identified by retrograde transport of a fluorescent label. Both serotonin (5-HT) and substance P (SP) excited virtually all neurons in the ISN. Application of these neuropeptides resulted in membrane depolarization that was concentration dependent. Although the majority of ISN neurons that were depolarized by SP application exhibited an increase in input resistance, application of 5-HT induced widely varied change in input resistance. Membrane depolarization elicited action potential discharges that increased in frequency with increasing concentration of 5-HT and SP. Blocking action potential conduction from surrounding neurons did not eliminate the depolarizing effects of 5-HT and SP, indicating that both neuropeptides acted directly on the ISN neurons. Finally, the use of 5-HT agonists and antagonists indicates that 5-HT acts via a 5-HT(2A) receptor, and the use of SP agonists suggests that SP acts via neuokinin-1 and -2 receptors. These data show that 5-HT and SP excite most of the ISN neurons innervating the lingual von Ebner glands possibly modulating the synaptic drive to these neurons derived from afferent gustatory input.


Asunto(s)
Tronco Encefálico/fisiología , Neuronas/efectos de los fármacos , Sistema Nervioso Parasimpático/fisiología , Salivación/fisiología , Serotonina/farmacología , Sustancia P/farmacología , Potenciales de Acción/efectos de los fármacos , Animales , Interpretación Estadística de Datos , Electrofisiología , Inmunohistoquímica , Sistema Nervioso Parasimpático/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Receptores de Neuroquinina-1/efectos de los fármacos , Receptores de Neuroquinina-2/efectos de los fármacos , Salivación/efectos de los fármacos , Antagonistas de la Serotonina/farmacología , Agonistas de Receptores de Serotonina/farmacología , Sustancia P/agonistas
15.
Bioorg Med Chem Lett ; 17(4): 890-4, 2007 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-17169559

RESUMEN

N-[(R,R)-(E)-(3,4-dichlorobenzyl)-3-(2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide (DNK333, 1b) has been reported to be a potent and balanced dual neurokinin (tachykinin) receptor antagonist. A recent clinical trial using DNK333 has shown that it blocks the NKA-induced bronchoconstriction in patients with asthma. A series of six analogues 3-8 derived from modification of 3,5-bis(trifluoromethyl)benzamide moiety of DNK333 has been synthesized to serve as the dual NK(1)/NK(2) receptor probes. The 3,5-dinitro substituted benzamide compound 3 was found to possess potent and balanced dual NK(1)/NK(2) receptor antagonist activities (pK(b)=8.4 for the NK(1) receptors, pK(b)=7.87 for the NK(2) receptors) in the functional assay using guinea pig trachea. Furthermore, SAR analysis suggests that steric, electronic, and lipophilic characteristics of substituents in the benzamide region of DNK333 have a crucial effect on both the NK(1) and NK(2) receptor antagonist activities.


Asunto(s)
Compuestos Aza/síntesis química , Compuestos Aza/farmacología , Benzamidas/síntesis química , Benzamidas/farmacología , Receptores de Neuroquinina-1/efectos de los fármacos , Receptores de Neuroquinina-2/efectos de los fármacos , Animales , Diseño de Fármacos , Cobayas , Técnicas In Vitro , Indicadores y Reactivos , Modelos Moleculares , Relación Estructura-Actividad , Tráquea/efectos de los fármacos
16.
Dig Dis Sci ; 51(3): 506-16, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16614960

RESUMEN

It is known that the muscularis mucosae and mucosa are not pharmacologically homogeneous throughout the rat colon. The aim of this study was to simultaneously characterize all three neurokinin (NK) receptors in the muscularis mucosae and mucosa along the length of the rat colon. Strips of proximal, mid, and distal colonic muscularis mucosae were prepared for isometric recording or sheets of muscle-free mucosa were mounted in Ussing chambers for measurement of short-circuit current. In both muscularis mucosae and mucosa the greatest responses to substance P were found in the proximal region. Use of selective agonists revealed the presence of all three NK receptors in both structures, however, selective antagonism suggests that only NK2 receptors in the muscularis mucosae and NK1 receptors in the mucosa are physiologically relevant. In conclusion, substance P-induced responses in the rat colon are region-specific and not mediated by a single NK receptor subtype common to both structures.


Asunto(s)
Acetilcolina/farmacología , Colon/efectos de los fármacos , Motilidad Gastrointestinal/efectos de los fármacos , Mucosa Intestinal/efectos de los fármacos , Receptores de Taquicininas/metabolismo , Sustancia P/farmacología , Animales , Colon/patología , Modelos Animales de Enfermedad , Femenino , Motilidad Gastrointestinal/fisiología , Mucosa Intestinal/patología , Masculino , Músculo Liso/efectos de los fármacos , Músculo Liso/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores de Neuroquinina-1/efectos de los fármacos , Receptores de Neuroquinina-1/metabolismo , Receptores de Neuroquinina-2/efectos de los fármacos , Receptores de Neuroquinina-2/metabolismo , Receptores de Taquicininas/efectos de los fármacos , Sensibilidad y Especificidad , Técnicas de Cultivo de Tejidos
17.
Br J Pharmacol ; 147(4): 430-6, 2006 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16402037

RESUMEN

1. The aim of the present study was to examine the role of NK1 and NK2 receptors in the control of mechanical activity of mouse stomach. In this view, the motor effects induced by NK1 and NK2 receptor agonists and antagonists were analyzed, measuring motility as intraluminal pressure changes in mouse-isolated stomach preparations. In parallel, immunohistochemical studies were performed to identify the location of NK1 and NK2 receptors on myenteric neurons and smooth muscle cells. 2. Substance P (SP) induced biphasic effects: a contraction followed by relaxation; neurokinin A (NKA) and [beta-Ala8]-NKA(4-10), selective agonist of NK2 receptors, evoked concentration-dependent contractions, whereas [Sar9, Met(O2)11]-SP, selective agonist of NK1 receptors, induced concentration-dependent relaxation. 3. SR48968, NK2 receptor antagonist, did not modify the spontaneous activity and reduced the contractile effects induced by tachykinins without affecting the relaxation. SR140333, NK1 receptor antagonist, did not modify the spontaneous activity and antagonized the relaxant response to tachykinins, failing to affect the contractile effects. 4. The relaxation to SP or to [Sar9, Met(O2)11]-SP was abolished by tetrodotoxin (TTX) and significantly reduced by N(omega)-nitro-L-arginine methyl ester (L-NAME). 5. NK2-immunoreactivity (NK2-IR) was seen at the level of the smooth muscle cells of both circular and longitudinal muscle layers. NK1-immunoreactive (NK1-IR) neurons were seen in the myenteric ganglia and NK1/nNOS double labeling revealed that some neurons were both NK1-IR and nNOS-IR. 6. These results suggest that, in mouse stomach, NK1 receptors, causing relaxant responses, are present on nitrergic inhibitory myenteric neurons, whereas NK2 receptors, mediating contractile responses, are present at muscular level.


Asunto(s)
Motilidad Gastrointestinal/efectos de los fármacos , Receptores de Neuroquinina-1/efectos de los fármacos , Receptores de Neuroquinina-1/fisiología , Receptores de Neuroquinina-2/efectos de los fármacos , Receptores de Neuroquinina-2/fisiología , Animales , Relación Dosis-Respuesta a Droga , Motilidad Gastrointestinal/fisiología , Inmunohistoquímica , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos , Neuroquinina A/farmacología , Antagonistas del Receptor de Neuroquinina-1 , Fragmentos de Péptidos/farmacología , Receptores de Neuroquinina-1/agonistas , Receptores de Neuroquinina-2/agonistas , Receptores de Neuroquinina-2/antagonistas & inhibidores , Sustancia P/farmacología
18.
Cell Signal ; 18(4): 422-32, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16009534

RESUMEN

The bone marrow (BM) is home to at least two stem cells, hematopoietic (HSC) and mesenchymal. Hematopoiesis is partly regulated through neurokinin-1 (NK-1) and NK-2 belonging to the family of G-protein/7-transmembrane receptors. NK-1 and NK-2 show preference for the neurotransmitters, substance P (SP) and neurokinin-A (NK-A), respectively. Hematopoietic suppression mediated by NK-A could be partly explained through the production of TGF-beta1 and MIP-1alpha. This study further characterizes mechanisms by which NK-A inhibits progenitor cell proliferation. The study addresses the hypothesis that p53 is a mediator of NK-A activation and this occurs partly through p53-mediated expression of NK-2. The studies first analyzed two consensus sequences for p53 in supershift assays. Reporter gene assays with NK-2 gene constructs and p53 expressing wild-type and mutant vectors, combined with cell proliferation assays, show NK-A activating p53 to inhibit the proliferation of K562 progenitors. These effects were reversed by hematopoietic stimulators, GM-CSF and SP. Verification studies with human CD34+/CD38- and CD34+/CD38+ BM progenitors show similar mechanisms with the expression of p21. This study reports on p53 as central to NK-A-NK-2 interaction in cell cycle quiescence of hematopoietic progenitors. These effects are reversed by at least two hematopoietic stimulators, SP and GM-CSF, with concomitant downregulation of p53.


Asunto(s)
Región de Flanqueo 5'/fisiología , Células Madre Hematopoyéticas/efectos de los fármacos , Neuroquinina A/farmacología , Receptores de Neuroquinina-2/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Ensayo de Cambio de Movilidad Electroforética , Regulación de la Expresión Génica/efectos de los fármacos , Factor Estimulante de Colonias de Granulocitos y Macrófagos/farmacología , Humanos , Células K562 , Neuroquinina A/genética , Neuroquinina A/metabolismo , ARN Mensajero/genética , Receptores de Neuroquinina-2/efectos de los fármacos , Receptores de Neuroquinina-2/genética , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Sustancia P/farmacología , Proteína p53 Supresora de Tumor/efectos de los fármacos , Proteína p53 Supresora de Tumor/genética
19.
Mol Cell Neurosci ; 30(4): 523-37, 2005 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-16202621

RESUMEN

Activation of intracellular signaling pathways involving p38 and p42/44 MAP kinases may contribute importantly to synaptic plasticity underlying spinal neuronal sensitization. Inhibitors of p38 or p42/44 pathways moderately attenuated responses of dorsal horn neurons evoked by mustard oil but not brush and alleviated the behavioral reflex sensitization seen following nerve injury. Activation of p38 and p42/44 MAP kinases in spinal cord ipsilateral to constriction injury was reduced by antagonists of NMDA, VPAC2 and NK2 (but not related) receptors, the glial inhibitor propentofylline and inhibitors of TNF-alpha. A VPAC2 receptor agonist enhanced p38 phosphorylation and caused behavioral reflex sensitization in naïve animals that could be blocked by co-administration of p38 inhibitor. Conversely, an NK2 receptor agonist activated p42/44 and caused behavioral sensitization that could be prevented by co-administration of p42/44 inhibitor. Thus, spinal p38 and p42/44 MAP kinases are activated in neuropathic pain states by mechanisms involving VPAC2, NK2, NMDA receptors and glial cytokine production.


Asunto(s)
Sistema de Señalización de MAP Quinasas/fisiología , Neuroglía/metabolismo , Enfermedades del Sistema Nervioso Periférico/metabolismo , Células del Asta Posterior/metabolismo , Receptores de Neuroquinina-2/metabolismo , Receptores de Tipo II del Péptido Intestinal Vasoactivo/metabolismo , Animales , Modelos Animales de Enfermedad , Activación Enzimática/efectos de los fármacos , Activación Enzimática/fisiología , Inhibidores Enzimáticos/farmacología , Mediadores de Inflamación/farmacología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Masculino , Proteína Quinasa 1 Activada por Mitógenos/efectos de los fármacos , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Neuralgia/metabolismo , Neuralgia/fisiopatología , Neuroglía/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Traumatismos de los Nervios Periféricos , Nervios Periféricos/metabolismo , Nervios Periféricos/fisiopatología , Enfermedades del Sistema Nervioso Periférico/fisiopatología , Fosforilación/efectos de los fármacos , Estimulación Física , Células del Asta Posterior/efectos de los fármacos , Ratas , Ratas Wistar , Receptores de N-Metil-D-Aspartato/efectos de los fármacos , Receptores de N-Metil-D-Aspartato/metabolismo , Receptores de Neuroquinina-2/efectos de los fármacos , Receptores de Tipo II del Péptido Intestinal Vasoactivo/efectos de los fármacos , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/metabolismo , Xantinas/farmacología , Proteínas Quinasas p38 Activadas por Mitógenos/efectos de los fármacos , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
20.
J Pharmacol Sci ; 94(4): 384-92, 2004 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15107578

RESUMEN

The aim of this work was to verify whether formalin would induce leukocyte recruitment following intraperitoneal (i.p.) injection in rats. Formalin (1.25 - 2.5%) induced cell recruitment, which was concentration- and time-dependent (0 - 24 h). Two peaks of leukocyte recruitment were observed. The first peak (from 2 to 4 h) was characterized by a mixed polymorphonuclear and lymphocyte cell population (representing an increase of 100 - 220% and 55 - 60%, respectively), whereas the second peak was characterized by a marked increase in lymphocytes at 24 h (representing an increase of 230%). Pretreatment of animals with specific antagonists for neurokinin NK(1), NK(2), and NK(3) receptors (SR140333, SR48968, and SR142801 compounds, respectively) reduced the early leukocyte increase (representing a significant reduction of 65%, 51%, and 46%, respectively), whereas only the treatment with NK(2)-specific antagonist reduced the late cell increase induced by formalin injection (amounting to a significant reduction of 48%). These results suggested that substance P, neurokinin A, and neurokinin B release accounted for formalin-induced cell migratory activity. The anti-inflammatory drug dexamethasone also reduced cell recruitment, which was mainly related to a reduction in 79% of the neutrophils at 4 h following 1.25% formalin injection, suggesting also a release of lipid mediators (eicosanoids and/or platelet-activating factor) and/or cytokines/chemokines by the formalin injection.


Asunto(s)
Formaldehído/administración & dosificación , Formaldehído/farmacología , Leucocitos/fisiología , Cavidad Peritoneal/fisiología , Receptores de Taquicininas/antagonistas & inhibidores , Animales , Benzamidas/farmacología , Movimiento Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Femenino , Inyecciones Intraperitoneales , Leucocitos/citología , Leucocitos/efectos de los fármacos , Modelos Biológicos , Neuroquinina A/metabolismo , Neuroquinina B/metabolismo , Antagonistas del Receptor de Neuroquinina-1 , Lavado Peritoneal , Piperidinas/farmacología , Quinuclidinas/farmacología , Ratas , Ratas Endogámicas , Receptores de Neuroquinina-1/efectos de los fármacos , Receptores de Neuroquinina-2/antagonistas & inhibidores , Receptores de Neuroquinina-2/efectos de los fármacos , Receptores de Neuroquinina-3/antagonistas & inhibidores , Receptores de Neuroquinina-3/efectos de los fármacos , Receptores de Taquicininas/efectos de los fármacos , Sustancia P/metabolismo , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA